Skip to main content
Access Bio, Inc. logo

Access Bio, Inc. — Investor Relations & Filings

Ticker · 950130 ISIN · KR8840090003 LEI · 335800Q5TV77F4L9Q648 KO Manufacturing
Open in API
Filings indexed 247 across all filing types
Latest filing 2022-12-12 Capital/Financing Update
Country IN India
Listing KO 950130

About Access Bio, Inc.

https://accessbio.net/

Access Bio, Inc. is a company dedicated to the prevention and early diagnosis of infectious diseases through the research, development, and manufacturing of in vitro diagnostic solutions. Its portfolio includes rapid diagnostic tests (RDTs), immunochemical diagnostics, biosensors, and molecular diagnostic products. The company is recognized for commercializing high-quality tests to combat significant global health threats, including malaria, COVID-19, HIV, and HPV. With a large-scale manufacturing capacity, Access Bio distributes its products globally, serving as a key partner in global health, particularly in the fight against often-neglected diseases.

Recent filings

Filing Released Lang Actions
전환사채(해외전환사채포함)발행후만기전사채취득(제5회차)
Capital/Financing Update Classification · 1% confidence The document is a regulatory filing from Access Bio regarding the acquisition of convertible bonds before maturity (a form of debt restructuring/capital structure change). It details the specific bond series, acquisition amount, and the reason for the acquisition (call option exercise). This falls under the category of capital and financing updates as it relates to the company's debt instruments and capital structure.
2022-12-12 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 1% confidence The document is a formal regulatory announcement regarding a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결) between Access Bio and the Defense Logistics Agency. It details the contract value, duration, and counterparty. Since this is a specific regulatory disclosure of a material business event (a contract win) that does not fit into the other specific categories like M&A or financial reports, it is classified as a general regulatory filing.
2022-11-23 Korean
기타경영사항(자율공시)(KDR 배당을 위한 투자자 유의사항(QI 자격을 취득한 계좌관리기관의 명단))
Notice of Dividend Amount Classification · 1% confidence The document is a regulatory filing from Access Bio regarding dividend-related tax procedures for KDR (Korea Depositary Receipts) holders. It provides a list of Qualified Intermediaries (QI) and instructions for investors to ensure proper tax withholding rates. While it relates to dividends, it is not a declaration of a dividend amount (DIV) but rather a procedural notice regarding tax compliance and account management for shareholders. As it does not fit into specific categories like DIV or SHA, it falls under the general regulatory announcement category.
2022-11-17 Korean
분기보고서 (2022.09)
Interim / Quarterly Report Classification · 1% confidence The document is a '분기보고서' (Quarterly Report) for Access Bio, covering the period from January 1, 2022, to September 30, 2022. It contains detailed financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2022
2022-11-14 Korean
현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정
Notice of Dividend Amount Classification · 1% confidence The document is a regulatory filing from Access Bio regarding the determination of a record date for shareholder registry closure for the purpose of cash/in-kind dividends. While it mentions dividends, it is not the announcement of the dividend amount itself (which would be DIV), but rather the procedural step of setting the record date for dividend eligibility. Given the nature of the filing as a corporate action announcement regarding shareholder rights and dividend preparation, it fits best under the general regulatory filing category as it is a specific corporate disclosure.
2022-11-01 Korean
수시공시의무관련사항(공정공시)(2022 사업연도 결산 이익배당 실시 계획)
Notice of Dividend Amount Classification · 1% confidence The document is an official announcement from Access Bio regarding their plan to implement a cash dividend for the 2022 fiscal year. It details the dividend scale, purpose, and the procedural requirements for shareholders (KDR holders) regarding tax withholding and currency conversion. Since it specifically announces the intention and details of a dividend payment, it falls under the 'Notice of Dividend Amount' category.
2022-11-01 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.